Clinical Trial Search

Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…

Primary: Objective Response (Partial and Complete) Per RECIST — 1 participants

Primary: Ability of PD-L1 to Predict Response — 0.377 Youden index

Primary: Response Assessment — 0; 0; 0; 0 Participants

Primary: 24 Week Progression Free Survival — 23 percentage of participants

Primary: Objective Response Rate, Complete (CR) or Partial (PR) Response — 5 percentage of participants

Primary: Best Overall Response by RECIST Criteria (Version 1.0) — 3; 0; 7; 6 eligible, treated participants

Primary: Phase II: Progression Free Survival Measured as Time From Randomization to First Observation of Objective Disease Relapse or Progression — 6.7; 6.8; 5.26 months

Primary: Objective Response Rate

Primary: Progression Free Survival (PFS) as Assessed by Independent Radiological Review — 2.5; 3.4 months — p=0.76

Primary: Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs) — 4; 0; 0; 1 Participants

Primary: Number of Participants With an Objective Response — 1; 0; 0; 0 Participants

Primary: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells (CD8/Treg) — 8.6 no unit of ratios with same units(%) — p=0.109

Primary: Progression Free Survival Rate at 6 Months — 56 percentage of participants

Primary: Progression-free Survival — 3.0; 3.4 months

Primary: Overall Response Rate — 9 percentage of participants

Primary: Safety/Toxicity — 0; 0 participants

Primary: Progression-free Survival (PFS) — 1.8 months

Primary: Disease Control Rate at 4 Months — 8 Participants

Primary: To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated…

Primary: Progression-Free Survival — 3.0 months

Primary: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee — 0 percentage of participants

Primary: Part 1: Pharmacokinetics Profile of Tazemetostat and Its Metabolite (Plasma): Cmax — 933 Ng/mL

Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125

Primary: Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6 — 26; 51 Participants

Primary: Overview of Adverse Events — 28; 23; 12; 1 participants

Primary: Recommended Phase 2 Dose (RP2D) of LMB100 + Nab-paclitaxel — 140; 100 mcg

Primary: Overall Survival — 17.6; 15.5 Months — p=0.2840

Primary: Pathological Complete Response — 3 participants

Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE) — 2…